Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 11/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217316 | 0.94 | ADORA2B (0.34) | FFAR1CTSAADORA2BADORA1ADORA2A | |
| SCHEMBL30217228 | 0.88 | CYP4F2 (0.42) | FFAR4CYP4F2CYP4A11 | |
| SCHEMBL30217105 | 0.82 | CYP4F2 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL30217199 | 0.82 | CDK8 (0.33) | — | |
| SCHEMBL30217154 | 0.81 | CNR2 (0.33) | — | |
| SCHEMBL30217297 | 0.79 | FFAR4 (0.34) | FFAR1FFAR4CYP4F2CYP4A11 | |
| SCHEMBL29237365 | 0.78 | FFAR1 (0.36) | FFAR1FFAR4 | |
| SCHEMBL30217365 | 0.77 | FFAR1 (0.37) | FFAR1FFAR4 | |
| SCHEMBL31108630 | 0.77 | FFAR1 (0.35) | FFAR1FFAR4 | |
| SCHEMBL29237410 | 0.77 | FFAR1 (0.35) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023034992-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |